62° AFI Symposium – Dr Pontello and Regola’s interview

During the Symposium session, attention will be paid to what factors are most likely to affect the prevention of contamination and cross-contamination

22/05/2023

AFI interviews

The third session of the Symposium focused on manufacturing and quality and issues related to the two fundamental aspects of pharmaceutical manufacturing: prevention of contamination and cross-contamination.

Alessandro Regola and Lino Pontello explained how to avoid the occurrence of these compromising eventualities in the drug manufacturing process. Innovation is the key word: innovation in procedures and innovation in production facilities.

Measures must be introduced to reduce the risk of contamination, especially for injectable drugs that have greater vulnerabilities, also following the new guidelines that Annex 1 has introduced. Dr. Pontello reminds us that the main source of risk and potential contamination is the operator himself, so good training and total sterility of the work environment are essential.

During the Symposium session, attention will be paid to what factors are most likely to affect the prevention of contamination and cross-contamination. Certainly the introduction of automated production processes will ensure levels of contamination prevention not otherwise achievable with traditional systems, totally eliminating the risk given to the operator himself.

One of the main pharmaceutical products to be subject to contamination is the biological drug, which is easily contaminated by viruses, and it is on this front that many innovative changes are taking place.

A hint also to the “clean by design” approach involving the validation of sterilization and quality control processes, which will also be covered at the Symposium: in fact, during the session there will be a moment dedicated to the so-called “cleanability” of pharmaceutical production equipment, a procedure that will be used to set parameters to be respected during the production stages. The introduction of a risk assessment will make it possible to maintain higher standards of cleanliness and sterilization.

All this, of course, with the greatest possible respect for the environment, which will be protected in the choice of chemicals for cleaning equipment.

NEWS

Latest updates from the pharma world


Health&Biotech Accelerator | Deloitte Officine Innovazione

The ultimate goal of the Health&BioTech Accelerator is to identify the most innovative companies globally that meet the innovation goals that the life sciences field is heading for.


ISPE Summer Night 2023

The 2023 edition of the event, which took place on 28 June at the Mudec – Museum of Cultures of Milan, was dedicated to digitization and automation in the pharmaceutical sector


Trends for the future of the pharmaceutical manufacturing

It’s now mandatory the full implementation of the Industry 4.0 paradigm.